GastroPlus在PK-PD结合模型的应用文章 （2012—2020年10月）

导  读

凡默谷技术部精取了2012-2020年10月GastroPlus在PK-PD结合模型中的应用文章9篇。

其中编号1-2的文章是2019年8月-2020年10月新增的文章。

希望对您的业务或专业学习有所帮助。内容如下：

1.  三种姜黄素口服制剂在大鼠中的药代动力学和药效学

Pharmacokinetics and pharmacodynamics of three oral formulations of curcumin in rats.

Wang L, Cheng D, Guo Y, Wu R, Yin R, Li S, Kuo HC, Hudlikar R, Yang H, Buckley B, Kong AN. J Pharmacokinet Pharmacodyn. (2020) 47:131–144. IF= 2.461

2.  联用生理药代动力学PBPK模型与药物-靶标滞留时间模型，预测托泊司他Topiroxostat在人体内的PK和PD

Prediction of the pharmacokinetics and pharmacodynamics of topiroxostat in humans by integrating the physiologically based pharmacokinetic model with the drug-target residence time model.

Zhiqiang Luo, Guohua Yu, Xing Han, Tingting Yang, Yanhua Ji, Huating Huang, Guopeng Wangc, Yang Liu, Wenyan Sun. Biomedicine & Pharmacotherapy. Volume 121, January 2020. IF=4.545

3.  咖啡因在孕妇体内处置的PBPK/PD模型

Physiologically Based Pharmacokinetic/ Pharmacodynamic Model for Caffeine Disposition in Pregnancy.

Darakjian LI, Kaddoumi A. Mol Pharm. Jan 28, 2019. IF=4.321

4.  采用PBPK/PD模型，通过大鼠和人的PK数据预测Buagafuran（强效抗焦虑剂）的治疗剂量

Prediction of a Therapeutic Dose for Buagafuran, a Potent Anxiolytic Agent by Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Starting from Pharmacokinetics in Rats and Human.

Fen Yang, Baolian Wang, Zhihao Liu, Xuejun Xia, Weijun Wang, Dali Yin, Li Sheng, Yan Li. Front Pharmacol. 2017; 8: 683. IF=4.225

5.  开发PBPK/PD模型，用于预测遗传多态性对受体/转运体占据的中枢神经系统药物PK与PD的影响

Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Predict the Impact of Genetic Polymorphisms on the Pharmacokinetics and Pharmacodynamics Represented by Receptor/Transporter Occupancy of Central Nervous System Drugs.

Alqahtani S, Kaddoumi A. (2016). Clin Pharmacokinet. Feb 25. IF=4.604

6.  开发PBPK/PD模型，以确定导致恩他卡朋生物利用度低的机制

Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model to Identify Mechanisms Contributing to Entacapone Low Bioavailability.

Alqahtani S, Kaddoumi A. (2015). Biopharm Drug Dispos. Aug 21. IF=1.663

7.  开发用于预测吲哚美辛在孕妇体内处置的PBPK/PD模型

Development of Physiologically Based Pharmacokinetic/Pharmacodynamic Model for Indomethacin Disposition in Pregnancy.

Alqahtani S, Kaddoumi A. (2015). PLoS One. Oct 2;10(10). IF=2.74

8.   人乳腺癌小鼠异种移植模型中多种凋亡抑制蛋白（IAPs）拮抗剂（SM-406 / AT-406）的PBPK-PD模型

Physiologically based pharmacokinetic and pharmacodynamic modeling of an antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in a mouse xenograft model of human breast cancer.

Zhang T, Li Y, Zou P, Yu JY, McEachern D, Wang S, Sun D. (2013) Biopharm. & Drug Dispos. DOI: 10.1002/bdd.1850. IF=1.663

9.   抗癌药物萝卜硫素在大鼠淋巴细胞中II相代谢/抗氧化酶基因反应的PK和PD

Pharmacokinetics and Pharmacodynamics of Phase II Drug Metabolizing/Antioxidant Enzymes Gene Response by Anti-cancer Agent Sulforaphane in Rat Lymphocytes.

Wang H, Khor TO, Yang Q, Huang Y, Wu TY, Saw CL, Lin W, Androulakis IP, Kong AN. (2012) Mol Pharm. Aug. 29. IF=4.321